In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U S corporate taxes.
| FactSnippet No. 1,401,572 |
In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U S corporate taxes.
| FactSnippet No. 1,401,572 |
Perrigo engages in the acquisition, manufacture, and sale of consumer healthcare products, generic prescription drugs, and active pharmaceutical ingredients, primarily in the United States, from its base in Ireland.
| FactSnippet No. 1,401,573 |
On 21 December 2018, Perrigo suffered its biggest one-day share price fall in its history after the Irish Revenue Commissioners issued a tax claim against Perrigo that equated to half of its market value.
| FactSnippet No. 1,401,574 |
Perrigo Company was founded in 1887 in Allegan, Michigan, by Luther and Charles Perrigo, who ran a general store.
| FactSnippet No. 1,401,575 |
In July 2013, Perrigo announced that it would execute a corporate tax inversion to Ireland in order to avoid U S corporate taxes, via an $8.
| FactSnippet No. 1,401,576 |
In May 2016, Perrigo investors sued the company over statements made during the Mylan bid, which were said to have persuaded shareholders to vote against the deal.
| FactSnippet No. 1,401,577 |
In September 2012, Perrigo announced its intention to enter the animal wellness category by acquiring the assets of Sergeant's Pet Care Products, Inc, a privately held manufacturer of over-the-counter companion animal healthcare products.
| FactSnippet No. 1,401,578 |
On 11 February 2013, Perrigo announced the completion of the acquisition of Rosemont Pharmaceuticals Ltd.
| FactSnippet No. 1,401,579 |
In November 2014, Perrigo announced it had agreed to buy Belgian health-products provider Omega Pharma approximately $4.
| FactSnippet No. 1,401,580 |
In May 2019, Perrigo announced it would acquire Ranir Global Holdings LLC, boosting its oral self-care offering, with the transaction valued at $750 million.
| FactSnippet No. 1,401,581 |
In March 2021, Perrigo confirmed it would sell off its generics business to Altaris Capital Partners for $1.
| FactSnippet No. 1,401,582 |